Empagliflozin and dapagliflozin show similar effectiveness in preventing cardiorenal outcomes among patients with type 2 diabetes without prior cardiovascular or renal disease.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/empagliflozin-vs-dapagliflozin-cardiorenal-prevention-t2d-2026a1000fmm?src=rss
Author :
Publish date : 2026-05-14 12:38:00
Copyright for syndicated content belongs to the linked Source.